CoolcatReport.com publisher Kevin Kennedy uses a proprietary trading and screening system, based in large part on momentum. For example, the stocks that make his buy list must be trading above their closes of 3, 6 and 12 months ago. In addition, they must have made new 52-week highs in the past two months.

Generally, Kennedy prefers stocks that have made new highs, have pulled back in a consolidation pattern, and are then poised to again move to new highs.

This basic strategy is applied to a wide range of stock ideas through his multiple Coolcat newsletter services. Small caps are featured in his Coolcat Explosive Small Cap Growth Stock Report.

“This batch of stocks is hanging out just above its 50-day moving average, offering some interesting entries with decent risks,” Kennedy says. “All have put earnings season to bed and appear well-positioned to move up from here.”

Passing Kennedy’s screening process is a trio of biotech stocks. Metabasis Therapeutics Inc. (Nasdaq: MBRX), says Kennedy, has a “promising pipeline” of preclinical and clinical product candidates targeting metabolic diseases such as diabetes, hyperlipidemia and obesity.

He notes that first-quarter revenues jumped 252% to $3.4 million, which included a $1.8-million upfront license fee received from Schering-Plough Corp. (NYSE: SGP) and license fee and sponsored research revenue from its hepatitis C collaboration with Idenix Pharmaceuticals Inc. (Nasdaq: IDIX).

The company – with a market cap of $243 million -- had $71.3 million in cash, cash equivalents and securities at the end of March, Kennedy notes.

Meanwhile, BioImaging Technologies Inc. (Nasdaq: BITI), with a market cap of $78 million, offers services to support the pharmaceutical, biotech and medical device industries in product development.

---You can read the FULL article when you register (registration is free!) or sign-in to SmallCapInvestor.com---